October 2, 2015 – The U.S. Food and Drug Administration (FDA) approved MorphaBond (morphine sulfate) extended release capsules, CII, manufactured by Inspirion Delivery. MorphaBond is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment, for which alternative treatment options are inadequate. Administered every 12 hours, MorphaBond is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse while maintaining its extended-release characteristics. Although MorphaBond is expected to reduce abuse or misuse through injection or intranasal administration, abuse via these routes is still possible. Product pricing and availability are currently unknown. MorphaBond will be available in 15mg, 30mg, 60mg, and 100mg tablets.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.